2891 - 2900 of 5882 Results
Title
Year
- Disease modifying treatment trials in Parkinson’s disease: how to balance expectations and interests of patients, physicians and industry partners?2020OPENTitle: Disease modifying treatment trials in Parkinson’s disease: how to balance expectations and interests of patients, physicians and industry partners?Journal Name: Neurological Research and PracticePublisher: Springer Science and Business Media LLCVol: 2Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s42466-020-00076-yBest OA location URL: https://neurolrespract.biomedcentral.com/track/pdf/10.1186/s42466-020-00076-yCitation Count: 2
-
OPENTitle: Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activityJournal Name: Biochemical JournalPublisher: Portland Press Ltd.Vol: 477Issue #: 22Start Page: 4397End Page: 4423Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1042/bcj20200458Best OA location URL: https://portlandpress.com/biochemj/article-pdf/477/22/4397/898287/bcj-2020-0458.pdfCitation Count: 67
- Globus Pallidus Internus (GPi) Deep Brain Stimulation for Parkinson’s Disease: Expert Review and Commentary2020OPENTitle: Globus Pallidus Internus (GPi) Deep Brain Stimulation for Parkinson’s Disease: Expert Review and CommentaryJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 10Issue #: 1Start Page: 7End Page: 30Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-020-00220-5Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-020-00220-5.pdfCitation Count: 41
-
OPENTitle: Lack of evidence for association of UQCRC1 with Parkinson's disease in EuropeansJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 101Issue #:Start Page: 297.e1End Page: 297.e4Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2020.10.030Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938960Citation Count: 8
- Estimation of Orofacial Kinematics in Parkinson’s Disease: Comparison of 2D and 3D Markerless Systems for Motion Tracking2020OPENTitle: Estimation of Orofacial Kinematics in Parkinson’s Disease: Comparison of 2D and 3D Markerless Systems for Motion TrackingJournal Name: 2020 15th IEEE International Conference on Automatic Face and Gesture Recognition (FG 2020)Publisher: IEEEVol:Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1109/fg47880.2020.00112Best OA location URL: https://arxiv.org/pdf/2003.08048Citation Count: 4
-
OPENTitle: Hitting the Bullseye: Are extracellular vesicles on target?Journal Name: Journal of Extracellular VesiclesPublisher: WileyVol: 10Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1002/jev2.12032Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jev2.12032Citation Count: 17
- <p>Sensory Hypersensitivity Severity and Association with Obsessive-Compulsive Symptoms in Adults with Tic Disorder</p>2020OPENTitle: <p>Sensory Hypersensitivity Severity and Association with Obsessive-Compulsive Symptoms in Adults with Tic Disorder</p>Journal Name: Neuropsychiatric Disease and TreatmentPublisher: Informa UK LimitedVol: Volume 16Issue #:Start Page: 2591End Page: 2601Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.2147/ndt.s274165Best OA location URL: https://www.dovepress.com/getfile.php?fileID=63218Citation Count: 16
- The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant2020OPENTitle: The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenantJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 80Issue #:Start Page: S54End Page: S63Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.10.027Best OA location URL: http://www.prd-journal.com/article/S135380202030818X/pdfCitation Count: 37
- Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4+, CD8+ T cells, and M1 macrophages2020OPENTitle: Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4+, CD8+ T cells, and M1 macrophagesJournal Name: Journal for ImmunoTherapy of CancerPublisher: BMJVol: 8Issue #: 2Start Page: e001617End Page: e001617Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1136/jitc-2020-001617Best OA location URL: https://jitc.bmj.com/content/jitc/8/2/e001617.full.pdfCitation Count: 37
-
OPENTitle: Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's diseaseJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 100Issue #:Start Page: 119.e7End Page: 119.e13Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2020.10.019Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940813Citation Count: 28